The association between metformin use, immune mediated colitis and overall survival in patients treated with checkpoint inhibitor

Genitourinary Cancer

The incidence of immune-related adverse events (irAEs) and their association with clinical outcomes in advanced renal cell carcinoma and urothelial carcinoma patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis

Cancer Treat Rev

Zhang Y, Chen J, Liu H, Dai J, Zhao J, Zhu S, Zhang X, Liang J, Hu X, Zhao J, Liu Z, Shen P, Sun G, Zeng H

doi: 10.1016/j.ctrv.2024.102787

Lung, Respiratory and Thoracic Cancer

Factors Associated with Disease Progression after Discontinuation of Immune Checkpoint Inhibitors for Immune-Related Toxicity in Patients with Advanced Non-Small Cell Lung Cancer

Clin Cancer Res

Pecci F, Thummalapalli R, Alden SL, Ricciuti B, Alessi JV, Elkrief A, Rizvi H, Wang X, Jeng M, Egger JV, Vaz VR, Barrichello A, Lamberti G, Di Federico A, Santo V, Rossato de Almeida G, Gandhi M, Clark P, Nishino M, Johnson BE, Hellmann M, Schoenfeld AJ, Awad MM

doi: 10.1158/1078-0432.CCR-24-2990

Genitourinary Cancer

Treatment options in first-line metastatic renal carcinoma: A meta-analysis of 2556 patients treated with immune checkpoint inhibitors-based combinations in randomised controlled trials

Cancer Treat Rev

Tucci M, Mandarà M, Giuliani J, Durante E, Buttigliero C, Turco F, Palesandro E, Campisi I, Singh N, Muraro M, Munoz F, Fiorica F

doi: 10.1016/j.ctrv.2024.102745

Lung, Respiratory and Thoracic Cancer

Use of immune checkpoint inhibitors in patients with lung cancer and multiple sclerosis

Lung Cancer

Iglesias Martinez B, Insa A, Cervera Ygual G, Gascón F, Domínguez Moran JA, Martín-Martorell P

doi: 10.1016/j.lungcan.2025.108464

Further Publications

From ICI to ICU: A systematic review of patients with solid tumors who are treated with immune checkpoint inhibitors (ICI) and admitted to the intensive care unit (ICU)

Cancer Treat Rev

van Dijk B, Janssen JC, van Daele PLA, de Jonge MJA, Joosse A, Verheul HMW, Epker JL, van der Veldt AAM

doi: 10.1016/j.ctrv.2025.102936

Further Publications

Circulating tumor DNA Clearance as a Predictive Biomarker of Pathologic Complete Response in Patients with Solid Tumors Treated with Neoadjuvant Immune-Checkpoint Inhibitors: a Systematic Review and Meta-Analysis

Ann Oncol

Valenza C, Saldanha EF, Gong Y, De Placido P, Gritsch D, Ortiz H, Trapani D, Conforti F, Cremolini C, Peters S, Mateo J, Subbiah V, Parsons HA, Partridge AH, Curigliano G

doi: 10.1016/j.annonc.2025.03.019

Skin Cancer

TNF signature in advanced melanoma patients treated with immune checkpoint inhibitors: Results from the MELANFα clinical study

Int J Cancer

Virazels M, Lusque A, Brayer S, Genais M, Dufau C, Milhès J, Filleron T, Pagès C, Sibaud V, Mortier L, Dereure O, Ayyoub M, Fabre A, Andrieu-Abadie N, Pancaldi V, Colacios C, Meyer N, Ségui B, Montfort A

doi: 10.1002/ijc.35416

Further Publications

Tocilizumab provides dual benefits in treating immune checkpoint inhibitor-associated arthritis and preventing relapse during ICI rechallenge: the TAPIR study

Ann Oncol

Petit PF, Daoudlarian D, Latifyan S, Bouchaab H, Mederos N, Doms J, Abdelhamid K, Ferahta N, Mencarelli L, Joo V, Bartolini R, Stravodimou A, Shabafrouz K, Pantaleo G, Peters S, Obeid M

doi: 10.1016/j.annonc.2024.08.2340

Skin Cancer

Shortened progression free and overall survival to immune-checkpoint inhibitors in BRAF-, RAS- and NF1- ("Triple") wild type melanomas

Eur J Cancer

Jansen P, Galetzka W, Lodde GC, Standl F, Zaremba A, Herbst R, Terheyden P, Utikal J, Pföhler C, Ulrich J, Kreuter A, Mohr P, Gutzmer R, Meier F, Dippel E, Weichenthal M, Placke JM, Landsberg J, Möller I, Sucker A, Paschen A, Hadaschik E, Zimmer L, Livingstone E, Schadendorf D, Ugurel S, Stang A, Griewank KG

doi: 10.1016/j.ejca.2024.114208

Related content

The incidence of immune-related adverse events (irAEs) and their association with clinical outcomes in advanced renal cell carcinoma and urothelial carcinoma patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis

Factors Associated with Disease Progression after Discontinuation of Immune Checkpoint Inhibitors for Immune-Related Toxicity in Patients with Advanced Non-Small Cell Lung Cancer

Treatment options in first-line metastatic renal carcinoma: A meta-analysis of 2556 patients treated with immune checkpoint inhibitors-based combinations in randomised controlled trials

Use of immune checkpoint inhibitors in patients with lung cancer and multiple sclerosis

From ICI to ICU: A systematic review of patients with solid tumors who are treated with immune checkpoint inhibitors (ICI) and admitted to the intensive care unit (ICU)

Circulating tumor DNA Clearance as a Predictive Biomarker of Pathologic Complete Response in Patients with Solid Tumors Treated with Neoadjuvant Immune-Checkpoint Inhibitors: a Systematic Review and Meta-Analysis

TNF signature in advanced melanoma patients treated with immune checkpoint inhibitors: Results from the MELANFα clinical study

Tocilizumab provides dual benefits in treating immune checkpoint inhibitor-associated arthritis and preventing relapse during ICI rechallenge: the TAPIR study

Shortened progression free and overall survival to immune-checkpoint inhibitors in BRAF-, RAS- and NF1- ("Triple") wild type melanomas